Tumor-associated antigen presented via major histocompatibility complex class I and class II on dendritic cells

Tumor-associated antigens (TAAs) are proteins or peptides, often derived from mutated or aberrantly expressed genes in tumor cells, that can be recognized as foreign by the immune system. Dendritic cells (professional antigen presenting cells) can process and present TAAs on both MHC class I (activating CD8+ cytotoxic T lymphocytes) and class II molecules (activating CD4+ helper T cells). Presentation through both pathways is crucial for mounting a robust and sustained anti-tumor immune response, engaging endogenous CTLs to recognize and kill tumor cells. Tumor immunotherapies, such as peptide or dendritic cell vaccines, aim to harness this pathway; major challenges include identification of appropriate antigens and ensuring effective presentation within the tumor microenvironment.

Other names

Tumor antigen presented by dendritic cellsTAA presented by MHC class I/IIDendritic cell-presented tumor antigenDC-mediated TAA presentation

Vaccination with dendritic cells loaded with tumor peptides leads to activation of both CD8+ CTLs via MHC class I and CD4+ helper T cells via MHC class II, resulting in a robust anti-tumor immune response.